Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model (SMART)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Anne Haroldsen, MHA
- Phone Number: (801) 507-9415
- Email: Anne.Haroldsen@imail.org
Study Contact Backup
- Name: Mark Durst
- Phone Number: 510-681-6862
- Email: Mark.Durst@imail.org
Study Locations
-
-
Utah
-
Murray, Utah, United States, 84017
- Intermountain Kidney Clinic
-
Murray, Utah, United States, 84107
- Dialysis Services
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females (≥ 18 years of age) with End Stage Kidney Disease undergoing in-center hemodialysis
- 150 days of hemoglobin readings and Aranesp doses without a hospitalization relevant to the condition of anemia
Exclusion Criteria:
- Inflammation as characterized by ferritin levels greater than 1000 ng/mL
- Patients with active cancer
- Patients with PTH greater than 1,000 pg/mL
- Active GI Bleed
- Hospitalization relevant to ESRD in last 150 days or during study
- Patients receiving Procrit rather than Aranesp.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Standard of care
All patients placed on dialysis receive standard of care
|
Current standard of care guidelines are followed for erythropoiesis-stimulating agents to control anemia in dialysis patients
|
|
Experimental: Model-based Aranesp doses
On entering the study cohort, patients will begin receiving doses calculated by the algorithm instead of by the standard of care procedures.
Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined.
The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been.
|
Patients will receive doses calculated by the algorithm instead of by the standard of care procedures.
Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined.
The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been.
The model-based dosing will be more flexible than the protocol-based dosing.
Some constraints in the protocol-based dosing were created to prevent patients from achieving high Hb levels.
The model-based dosing will also prevent these high Hb values but will do so by predicting a patient's Hb level into the future and then using these predictions to determine doses to reduce Hb variability and to reduce the amount of Aranesp used.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction of hemoglobin cycling in dialysis patients
Time Frame: 90 days after the intervention
|
Reduction of hemoglobin cycling
|
90 days after the intervention
|
|
Time hemoglobin levels are maintained within acceptable range
Time Frame: 90 days after the intervention
|
Time hemoglobin levels are maintained within acceptable range
|
90 days after the intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction in quantity of drug administered to patients
Time Frame: 90 days after the intervention
|
Reduction in quantity of drug administered to patients
|
90 days after the intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chemiti Gopal, MD, Intermountain Health Care, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Disease Attributes
- Hematologic Diseases
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Kidney Failure, Chronic
- Anemia
- Hematinics
- Darbepoetin alfa
Other Study ID Numbers
Other Study ID Numbers
- SMaRT Study (Other Identifier: UHN)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.